Pioglitazone may impair L‐DOPA anti‐parkinsonian efficacy in the MPTP ‐lesioned macaque: Results of a pilot study
Synapse · 2015-03 · 69 (3) · 99-102
DOI: 10.1002/syn.21801 ↗At a glance
Journal article in Synapse, published online on 2015-01-20. Written by Philippe Huot and 3 co-authors. Institution: Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada; Division of Neurology, Movement Disorder Clinic, Toronto Wes…. Cited 7 times so far (Crossref); 21 references. Funded by: National Institutes of Health, Parkinson Society Canada, Canadian Institutes of Health Research.
Abstract (original language)
Santrauka nepasiekiama.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada; Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
Funding
- National Institutes of Health
- Parkinson Society Canada
- Canadian Institutes of Health Research
- Merck & Co., Inc.
- Teva Pharmaceutical Industries
- Atuka Ltd.
- Edmond J Safra Philanthropic Foundation
- Krembil Foundation
Cite
APA
Huot, P., Johnston, T. H., Fox, S. H., & Brotchie, J. M. (2015). Pioglitazone may impair L‐DOPA anti‐parkinsonian efficacy in the MPTP ‐lesioned macaque: Results of a pilot study. Synapse, 69(3), 99-102. https://doi.org/10.1002/syn.21801
Vancouver
Huot P, Johnston TH, Fox SH, Brotchie JM. Pioglitazone may impair L‐DOPA anti‐parkinsonian efficacy in the MPTP ‐lesioned macaque: Results of a pilot study. Synapse. 2015;69(3):99-102. doi:10.1002/syn.21801
BibTeX
@article{Huot2015,
author = {Huot, Philippe and Johnston, Tom H and Fox, Susan H and Brotchie, Jonathan M},
title = {Pioglitazone may impair L‐DOPA anti‐parkinsonian efficacy in the MPTP ‐lesioned macaque: Results of a pilot study},
journal = {Synapse},
year = {2015},
volume = {69},
number = {3},
pages = {99--102},
doi = {10.1002/syn.21801}
}
EUVIMED